Abstract: A hydrophilic semipermeable hollow-fiber membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fiber membrane possesses on its inner surface a separating layer and an adjoining open-pored supporting layer, and has an ultrafiltration rate in albumin solution of 5 to 25 ml/(h·m2·mmHg). The hollow-fiber membrane is free from pore-stabilizing additives and has a maximum sieving coefficient for albumin of 0.005 and a sieving coefficient for cytochrome c that satisfies the equation SCCC?5·10?5·UFRAlb3?0.004·UFRAlb2+1.081·UFRAlb?0.25.

Abstract: A hydrophilic, semipermeable hollow-fiber membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fiber membrane possesses on its inner surface a porous separating layer and an open-pored supporting layer adjoining the separating layer, and has an ultrafiltration rate in albumin solution of 25 to 60 ml/(h·m2·mmHg). The hollow-fiber membrane is free from pore-stabilizing additives, and has a minimum sieving coefficient for cytochrome c of 0.8 and maximum sieving coefficient for albumin of 0.005.

Abstract: A hydrophilic semipermeable hollow-fibre membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fiber membrane possess on its inner surface a separating layer and an adjoining open-pored supporting layer, and has an ultrafiltration rate in albumin solution of 5 to ?25 ml/(h·m2·mmHg). The hollow fiber membrane is free from pore-stabilizing additives and has a maximum sieving coefficient for albumin of 0.005 and a sieving coefficient of cytochrome c that satisfies the equation SCcc?5·10?5·UFRAlb3?0.004·UFRAlb2+0.1081·UFRAlb?0.25.

Abstract: A hydrophilic semipermeable hollow-fibre membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fibre membrane possesses on its inner surface a separating layer and an adjoining open-pored supporting layer, and has an ultrafiltration rate in albumin solution of 5 to 25 ml/(h·m2·mmHg). The hollow-fibre membrane is free from pore-stabilising additives and has a maximum sieving coefficient for albumin of 0.005 and a sieving coefficient for cytochrome c that satisfies the equation SCCC?5·10?5·UFRAlb3?0.004·UFRAlb2+1.081·UFRAlb?0.

Abstract: A hydrophilic, semipermeable hollow-fibre membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fibre membrane possesses on its inner surface a porous separating layer and an open-pored supporting layer adjoining the separating layer, and has an ultrafiltration rate in albumin solution of 25 to 60 ml/(h·m2·mmHg). The hollow-fibre membrane is free from pore-stabilising additives, and has a minimum sieving coefficient for cytochrome c of 0.8 and maximum sieving coefficient for albumin of 0.005.

Abstract: A hydrophilic semipermeable hollow-fibre membrane for blood treatment, with an integrally asymmetric structure based on a synthetic polymer. The hollow-fibre membrane possesses on its inner surface a separating layer and an adjoining open-pored supporting layer, and has an ultrafiltration rate in albumin solution of 5 to 25 ml/(h·m2·mmHg). The hollow-fibre membrane is free from pore-stabilizing additives and has a maximum sieving coefficient for albumin of 0.005 and a sieving coefficient for cytochrome c that satisfies the equation SCCC?5·10?5·UFRAlb3?0.004·UFRAlb2+1.081·UFRAlb?0.

Abstract: AGE precursors can be removed from blood, plasma or PBS buffer using a modified polymeric shaped body that can be produced by reaction of diaminoguanidine and/or triaminoguannidine with a staring polymeric shaped body carrying R—X residues, where R is an alkylene group that may or may not be substituted with a hydroxyl group and contains from 1 to 3 carbon atom, and X is a group that is substituted during the reaction by carrying residues Y, on to with diaminoguanidine, or with a starting polymeric shaped body during the reaction which diaminoguanidine and/or triaminoguannidine are added during the reaction.

Abstract: A molded body containing a polyarylether, at the surface of which substituents of formula —(R1—C—R2)—X are bound, where R1?H or an alkyl residue with 1 to 4 C atoms, R2?H or an alkyl residue with 1 to 4 C atoms, and X is a residue of formula NH—(O?C)—CH2-A, where A=F, Cl, Br or I or (CH2)pCHNH2—COOH with p=1 or 2, or a residue of formula NH—(CH2)n—CH2—Y, where Y?H or NH2 and n is an integer between 0 and 6, or a residue of formula O—(CH2)mCH2-Z, where Z=H, OH, COOH, NH2, N-pyrrolidone or N-pyrrolidine and m is an integer between 1 and 5, or a residue of formula NH—NH—(C?NH)—NH2, or a residue of formula NH—(O?C)—CR3?CH2 where R3?H or CH3, or a residue of formula O—(O?C)—(CH2)k-L, where L=COOH or NH2 and k is an integer between 1 and 10, or a residue of formula NH—(O?C)-Ph, where Ph is an unsubstituted or pentahalogenated phenyl residue, or a residue of formula O-G, where G is a glucose residue or glucosamine residue. Also the method for producing such a molded body.

Abstract: AGE precursors can be removed from blood, plasma or PBS buffer using a modified polymeric shaped body that can be produced by reaction of diaminoguanidine and/or triaminoguanidine with a starting polymeric shaped body carrying R—X residues, where R is an alkylene group that may or may not be substituted with a hydroxyl group and contains from 1 to 3 carbon atoms, and X is a group that is substituted during the reaction by diaminoguanidine and/or triaminoguanidine, or with a starting polymeric shaped body carrying residues Y, on to which diaminoguanidine and/or triaminoguanidine are added during the reaction.